Related references
Note: Only part of the references are listed.Molecular Imaging of Changes in the Prevalence of Vascular Endothelial Growth Factor Receptor in Sunitinib-Treated Murine Mammary Tumors
Zoia Levashova et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Bioengineering a Unique Deimmunized Bispecific Targeted Toxin That Simultaneously Recognizes Human CD22 and CD19 Receptors in a Mouse Model of B-Cell Metastases
Daniel A. Vallera et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Noninvasive assessment of tumor VEGF receptors in response to treatment with Pazopanib: A molecular imaging study
Francis G. Blankenberg et al.
TRANSLATIONAL ONCOLOGY (2010)
Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
Wolfram C. M. Dempke et al.
EUROPEAN JOURNAL OF CANCER (2009)
Can Tyrosine Kinase inhibitors be Discontinued in Patients with Metastatic Renal Cell Carcinoma and a Complete Response to Treatment? A Multicentre, Retrospective Analysis
Manfred Johannsen et al.
EUROPEAN UROLOGY (2009)
Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition
Alexandre Bozec et al.
EUROPEAN JOURNAL OF CANCER (2008)
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder
LuCheng Liu et al.
UROLOGIA INTERNATIONALIS (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
Yong S. Chang et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes
Marina V. Backer et al.
NATURE MEDICINE (2007)
Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas
Toshiyuki Nakayama et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2006)
Rapid vascular regrowth in tumors after reversal of VEGF inhibition
Michael R. Mancuso et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Predicting benefit from anti-angiogenic agents in malignancy
Adrian M. Jubb et al.
NATURE REVIEWS CANCER (2006)
Shiga toxin 1 induces apoptosis in the human myelogenous leukemia cell line THP-1 by a caspase-8-dependent, tumor necrosis factor receptor-independent mechanism
SY Lee et al.
INFECTION AND IMMUNITY (2005)
Novel protein targeted therapy of metastatic melanoma
AE Frankel et al.
CURRENT PHARMACEUTICAL DESIGN (2003)
Escherichia coli Shiga-like toxins induce apoptosis and cleavage of poly(ADP-ribose) polymerase via in vitro activation of caspases
JCY Ching et al.
INFECTION AND IMMUNITY (2002)
In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors
LM Veenendaal et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Targeting endothelial cells overexpressing VEGFR-2: Selective toxicity of Shiga-like toxin-VEGF fusion proteins
MV Backer et al.
BIOCONJUGATE CHEMISTRY (2001)
Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck
C Neuchrist et al.
LARYNGOSCOPE (2001)
Functionally active VEGF fusion proteins
MV Backer et al.
PROTEIN EXPRESSION AND PURIFICATION (2001)
Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2
MV Backer et al.
JOURNAL OF CONTROLLED RELEASE (2001)